We are live on ! Find out more
AGRX

Agile Therapeutics

Delisted

AGRX was delisted on the 25th of March, 2024.

45 hedge funds and large institutions have $161M invested in Agile Therapeutics in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

43% more capital invested

Capital invested by funds: $113M → $161M (+$48.5M)

33% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 9

0% more funds holding

Funds holding: 4545 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

Holders
45
Holders Change
Holders Change %
0%
% of All Funds
1.18%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.1%
New
4
Increased
12
Reduced
9
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
ACP
51
Acuta Capital Partners
California
-$952K -71 Closed
LTFS
52
Ladenburg Thalmann Financial Services
Florida
-$10K -1 Closed
Walleye Trading
53
Walleye Trading
New York
-$7K -1 Closed

AGRX Hedge Fund Activity: Q4 2015 in Review

45 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q4 2015, worth a combined $161M — up 43% from $113M a quarter earlier.

Fund positioning in AGRX was balanced in Q4 2015: 4 funds opened new positions, 4 closed out, 12 added to existing stakes and 9 trimmed.

The largest buyer was Senzar Asset Management, opening a new position worth an estimated $3.05M. The largest seller was RA Capital Management, exiting entirely with an estimated $4.25M sold.

  • 45 institutional investors held Agile Therapeutics (AGRX) as of Q4 2015, unchanged from Q3 2015.
  • Funds reported $161M of Agile Therapeutics stock for Q4 2015, up 43% quarter-over-quarter.
  • 4 funds opened new Agile Therapeutics positions in Q4 2015 and 4 closed out, a net change of 0 holders.
  • The largest Agile Therapeutics buyer in Q4 2015 was Senzar Asset Management, an estimated $3.05M added.
  • The largest Agile Therapeutics seller in Q4 2015 was RA Capital Management, an estimated $4.25M sold.

Based on aggregated 13F filings for Q4 2015.